PANOVA-3
-
Zai Lab and Novocure to Present PANOVA-3 Trial Results for TTFields Therapy in Pancreatic Cancer at 2025 ASCO Annual Meeting
A Phase 3 trial (PANOVA-3) showed that Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel improved overall survival in patients with unresectable, locally advanced pancreatic cancer and reduced pain duration compared to chemotherapy alone. The results are published in the *Journal of Clinical Oncology* and will be presented at ASCO. Novocure plans to submit the data to the FDA for approval.
